Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Metastatic castration-resistant prostate cancer, drawn from the whole corpus: 87 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
The best sequence of radioligand, PARP inhibitor and chemotherapy is untested.
Actinium-225 supply and the lack of alpha-emitter dosimetry.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Lineage plasticity to neuroendocrine disease under androgen receptor blockade.
Resistance to 177Lu-PSMA-617 in PSMA-low or FDG-discordant disease.
Nothing recorded yet.
Also on OnCo: Resistance atlas · Lines of therapy.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 40 changes by month →When this page itself was last checked or edited.
PSMA+ mCRPC after ARPI, before chemotherapy (PSMAfore)
PSMA+ mCRPC after ARPI, before chemotherapy
rPFS significantly improved.
A milestone in how this cancer is treated.
rPFS HR 0.